LMNA (Lamin A/C)

Details

LMNA encodes lamins A and C, nuclear envelope proteins that form the structural scaffold of the cell nucleus and participate in mechanosensing. LMNA variants cause a highly penetrant form of ACM with a distinctive clinical phenotype: conduction disease and atrial fibrillation preceding ventricular arrhythmias and cardiomyopathy by years to decades. LMNA-associated ACM is among the highest-risk inherited cardiomyopathies for malignant ventricular arrhythmias.

Epidemiology

• Clinical sequence: AF and cardiac conduction disease (PR prolongation → AV block) characteristically precede development of ventricular arrhythmias and DCM/ALVC phenotype — sometimes by decades. This sequential progression is pathognomonic of LMNA disease. (sources/acm-hrs-2019)
• Prevalence in CCD + DCM: LMNA variants found in ~6% of DCM patients, up to 10% in familial DCM, and up to 33% in patients with both DCM and conduction disorders — the highest-yield subgroup for LMNA genetic testing. In young adults, early conduction defects and arrhythmias typically precede LV dysfunction and dilatation, manifesting in the 3rd or 4th decade of life. (sources/conduction-disorders-jaha-2025, rating: high)
• Systemic phenotypes: LMNA variants produce an array of phenotypes including Emery-Dreifuss muscular dystrophy, generalized lipodystrophy, DCM with HF, progressive conduction disease with late-onset DCM, and ALVC. This phenotypic heterogeneity is not well explained by genotype alone. (sources/acm-hrs-2019)
• Early-onset AF: LMNA was the 4th most common gene with P/LP variants in 1293 patients with early-onset AF (WGS cohort): 9 participants (6% of all disease-associated variants); median AF diagnosis age 52 years (IQR 41–52). This aligns with the known LMNA clinical sequence — AF and conduction disease appear first, preceding ventricular involvement by years to decades. (sources/eoaf-jama-2021)
• AF <40 without overt structural disease: In a prospective cohort of AF before age 40 specifically excluding structural heart disease and major comorbidities, 2 of 8 P/LP variant carriers harbored LMNA variants. CMR was performed in 49% of the cohort and showed normal ventricular volumes without scar or fibrosis. This confirms that LMNA-related disease can present as isolated AF in young patients before cardiomyopathy becomes structurally detectable — consistent with the known LMNA sequence of AF preceding ventricular disease. (sources/eoaf-riskfactor-ehj-2026, rating: medium)
• Combined cardiomyopathy + arrhythmia panel: In a real-world cohort of 4,782 patients (combined 150-gene panel), LMNA is explicitly categorised as one of 10 genes associated with heightened arrhythmia risk in cardiomyopathy — alongside ABCC9, DES, DSP, FLNC, PLN, RBM20, RYR2, SCN5A, and TTN. Patients carrying P/LP variants in this gene group (300 patients, 31.4% of all positives) warranted more intensive cardiac monitoring and/or device intervention to address AF, VT, and/or heart block. (sources/genetic-yield-jama-card-2022, rating: high)

Pathophysiology

• Nuclear functions of Lamin A/C: Lamins A and C form structural filaments at the inner nuclear membrane and are essential for nuclear stability, chromatin organisation, gene expression regulation, and DNA damage repair. LMNA mutations disrupt these functions → cardiac fibrosis, abnormal response to mechanical stress, defective electrical signalling, impaired autophagy, and upregulation of MAPK (mitogen-activated protein kinase) and mTOR (mammalian target of rapamycin) signalling pathways. (sources/HF-Precision-Medicine-AHA-2019, rating: high)
• Gene class: Nuclear envelope (NE) protein; truncating and missense variants are both pathogenic. (sources/HF-Precision-Medicine-AHA-2019, rating: high)
• REALM-DCM Phase 3 failure: The REALM-DCM trial (phase 3, placebo-controlled) tested a p38α-MAPK inhibitor (PF-07265803/ARRY-371797) specifically in symptomatic LMNA-related DCM — and showed no benefit. LMNA controls nuclear function not only in cardiomyocytes but also in fibroblasts, endothelial cells, and inflammatory cells simultaneously; cardiac transcriptomes show enrichment of both cardiomyocyte survival transcripts and reactive fibrosis transcripts. This failure demonstrates that single-pathway targeting is insufficient for LMNA-DCM and that the pathophysiology is highly complex. (sources/DCM-Lancet-2023, rating: very high)
• Cardiac transcriptomic profile: Cardiomyocyte survival and reactive fibrosis transcripts are enriched in laminopathies. At end-stage, the molecular profile of LMNA-DCM is distinct from TTNtv-DCM, with a larger pro-fibrotic and inflammatory signature — partly explaining the resistance to conventional HF therapies. (sources/DCM-Lancet-2023, rating: very high)
• Atrial myopathy and thromboembolic risk: LMNA cardiomyopathy is associated with prominent atrial fibrosis, markedly impaired atrial mechanical function, and risk of atrial standstill — mechanisms that substantially elevate thromboembolic risk beyond what CHA2DS2-VASc scoring captures. LMNA-related DCM carries thromboembolic risk up to five times higher than other DCM subtypes with atrial arrhythmias. (sources/DCM-Lancet-2023, rating: very high) (sources/genetic-af-cjc-2024, rating: high)

Clinical Presentation

• Pathognomonic sequence: AF and cardiac conduction disease → progressive AV block → ventricular arrhythmias → DCM/ALVC phenotype — sometimes over decades. (sources/acm-hrs-2019)
• Systemic phenotypes: Emery-Dreifuss muscular dystrophy, generalized lipodystrophy, DCM with HF, progressive conduction disease with late-onset DCM, and ALVC. Phenotypic heterogeneity is not well explained by genotype alone. (sources/acm-hrs-2019)
• CJC 2024 — Laminopathy presenting as AF with AV block: A 52-year-old woman with persistent AF and normal biventricular function had a father who died suddenly at 50 and received a pacemaker at 41. Post-cardioversion ECG revealed marked sinus bradycardia and first-degree AV delay. Genetic testing identified a pathogenic LMNA splice site variant (c.356+2T>G). Key clinical clue: AF with spontaneous AV conduction slowing (slow ventricular rate) + family history of sudden death/pacemaker strongly suggests laminopathy. (sources/genetic-af-cjc-2024, rating: high)
• Septal mid-wall LGE: Characteristic CMR pattern for LMNA-related NDLVC/DCM, helping distinguish from DSP/FLNC ring-like LGE or PLN inferolateral patterns. (sources/esc-cmp-2023)
• NDLVC classification: Patients with LMNA variants showing non-dilated LV + fibrosis without meeting DCM dilatation criteria are now classified under NDLVC rather than ACM/ALVC per ESC 2023. (sources/esc-cmp-2023)

Diagnosis & Risk Stratification

• Genetic testing — Class I (ESC 2022): LMNA must be included in the DCM/HNDCM genetic panel for patients with AV conduction delay <50 years or family history of SCD <50 years. (sources/VA-SCD-ESC-2022)
• Genetic testing — COR 2a (AHA 2022): Referral for genetic counseling and testing is "reasonable" in select patients with nonischemic cardiomyopathy to identify conditions guiding treatment for patients and family members. (sources/HF-AHA-2022, rating: very high)
• Minimum DCM gene panel must include LMNA alongside TTN, MYH7, MYPC, TNNT, RBM20, PLN, SCN5a, BAG3, and others (ESC 2021). (sources/HF-ESC-2021, rating: very high)
• CMR preferred over echocardiography for surveillance in LMNA-positive EOAF patients — septal mid-wall LGE may be the first structural abnormality. (sources/genetic-eoaf-ehj-2024, rating: high)
• LMNA risk-VTA calculator (https://lmna-risk-vta.fr) is specifically recommended to guide primary prevention ICD decisions. ESC 2023 recommends this tool while noting the 2022 ESC VA guidelines suggest a 10% threshold — creating an internal ESC inconsistency. (sources/esc-cmp-2023)
• 4-factor risk model (ESC 2021): (1) NSVT on ambulatory ECG monitoring, (2) LVEF <45% at first evaluation, (3) male sex, (4) non-missense mutations (insertions, deletions, truncations, mutations affecting splicing). Risk increases exponentially: 9% with 1 risk factor → 69% with 4 risk factors. (sources/HF-ESC-2021, rating: very high)
• VA meta-analysis (DCM, n=11,451): LMNA mutations significantly associated with sustained VA in a prior genotype-phenotype meta-analysis (Kayvanpour 2017, referenced in Sammani 2020); could not be pooled as a standalone HR in the 2020 meta-analysis, but LMNA is among three gene variants (with PLN and FLNC) singled out as important non-pooled predictors. (sources/VA-DCM-Sammani-2020)
• LMNA as sentinel for EOAF genetic testing: LMNA is one of the most clinically actionable cardiomyopathy genes identified in EOAF cohorts. In EOAF patients found to carry LMNA variants, increased surveillance and early consideration of ICD (before LVEF falls to ≤35%) is warranted even when ventricular findings on initial echocardiography are absent, because AF may precede structural cardiomyopathy by years. (sources/genetic-eoaf-ehj-2024, rating: high)

Management

ICD

• ESC 2021 — ICD over pacemaker for LMNA-related CCD: When a pacing indication exists in LMNA disease, an ICD with pacing capability is preferred over a standard pacemaker — given the high concurrent risk of malignant ventricular arrhythmias even at the time of pacing indication. This is a fundamental management principle for LMNA-related conduction disease. (sources/conduction-disorders-jaha-2025, rating: high)
• HRS 2019 — COR IIa, LOE B-NR: ICD reasonable if ≥2 of: NSVT, LVEF <45%, male sex. If indication for pacing exists, implant ICD with pacing capabilities (AV block is a univariate predictor of VT/VF in some cohorts). (sources/acm-hrs-2019)
• ESC 2021 — ICD risk stratification in DCM: LMNA, RBM20, PLN, and FLN are all identified as genotypes warranting early ICD consideration. ESC 2021 uses the 4-factor model (NSVT, LVEF <45%, male sex, non-missense) with exponential risk increase. (sources/HF-ESC-2021, rating: very high)
• ESC 2022 — ICD Class IIa: ICD when LVEF <50% + ≥2 risk factors (LMNA mutation counts as one risk factor; others: syncope, LGE on CMR, inducible SMVT at PES). Distinct from the LMNA-specific VTA calculator threshold (≥10%) endorsed elsewhere — an internal ESC inconsistency. (sources/VA-SCD-ESC-2022)
• ESC 2023 — DCM/NDLVC context: ICD should be considered in LMNA carriers with LVEF >35% if additional risk factors are present (NSVT, syncope, LGE on CMR) — Class IIa, Level C. Endorses the LMNA risk-VTA calculator. (sources/esc-cmp-2023)
• AHA 2022 — ICD for genetic variants at higher LVEF (COR 2a): Identification of pathogenic variants in LMNA/C, desmosomal proteins, phospholamban, and FLNC may trigger consideration of primary prevention ICD even in patients with LVEF >35% or <3 months of GDMT. Most LMNA cardiomyopathy patients progress to transplantation — sometimes precipitated by refractory arrhythmias more than pump failure. (sources/HF-AHA-2022, rating: very high)
• HFSA 2018 — Early ICD before LVEF <35% (Level C): In LMNA cardiomyopathy and other genes with prominent early arrhythmia risk (DES, SCN5A, FLNC), an ICD may be considered before the LVEF falls below 35%. Because LMNA cardiomyopathy progresses through conduction disease + AF + VA before LV dysfunction becomes advanced, the standard LVEF ≤35% threshold leaves patients unprotected during the highest arrhythmia-risk period. When a pacemaker indication exists, an ICD with pacing capability should be implanted rather than a pacemaker alone. For patients likely to require chronic ventricular pacing with reduced EF, a CRT-defibrillator should be considered. (sources/genetic-cmp-jcf-2018, rating: very high)

Pharmacotherapy

• Standard HF pharmacotherapy (ACEi/ARNI + beta-blocker + MRA + SGLT2i) applies to LMNA-associated DCM without modification; LMNA-specific management is ICD risk stratification. (sources/HF-ESC-2021, rating: very high)
• TRED-HF pilot data: In non-ischaemic DCM achieving partial/complete LVEF recovery on therapy, 44% relapsed within 6 months after drug withdrawal — supporting continuation of medical therapy even in apparent recovery, relevant to LMNA patients who may transiently improve. (sources/HF-ESC-2021)
• OAC regardless of CHA2DS2-VASc in laminopathy: OAC is strongly recommended in LMNA-DCM with AF, beyond standard CHA2DS2-VA threshold considerations, due to prominent atrial fibrosis, impaired atrial mechanical function, and risk of atrial standstill. (sources/genetic-af-cjc-2024, rating: high) (sources/DCM-Lancet-2023, rating: very high)
• Rate control preferred over rhythm control: Rhythm control is futile in established cardiac laminopathy due to progressive atrial myopathy and high AF recurrence. The CJC 2024 case explicitly chose rate control over rhythm control after LMNA diagnosis, and long-term OAC was prescribed regardless of CHA2DS2-VASc score. (sources/genetic-af-cjc-2024, rating: high)
• Caution with sodium channel blockers: When LMNA carriers require rhythm control for AF, caution should be taken — LMNA-specific drug caution relates to antiarrhythmic selection in conjunction with the underlying conduction disease phenotype. (sources/genetic-eoaf-ehj-2024, rating: high)

Catheter Ablation

• VT ablation — poor outcomes: VT ablation in LMNA cardiomyopathy has high arrhythmia recurrence rate, rapid progression to end-stage HF, and high mortality. Ablation should be considered only as a bridge or adjunct. (sources/acm-hrs-2019)
• AF ablation — dismal outcomes: Patients with pathogenic LMNA variants and associated cardiomyopathy have poor long-term outcomes with catheter ablation for AF — consistent with the progressive atrial myopathy and fibrosis that characterises LMNA disease. (sources/genetic-af-cjc-2024, rating: high)

Exercise Restriction

• ESC 2022 — Class III: Competitive sports and high-intensity exercise are NOT recommended for individuals with DCM/HNDCM and an LMNA mutation. (sources/VA-SCD-ESC-2022)

Contradictions / Open Questions

• ESC VA 2022 vs. ESC CMP 2023 ICD threshold inconsistency: ESC VA 2022 recommends ICD in DCM/HNDCM + LVEF <50% + ≥2 risk factors (where LMNA mutation counts as one factor). ESC CMP 2023 instead endorses the LMNA risk-VTA calculator (https://lmna-risk-vta.fr) with an implied ≥10% threshold, and explicitly notes this creates an internal ESC inconsistency. Clinicians managing LMNA patients face different thresholds from two current ESC guidelines — the more genotype-inclusive CMP 2023 approach permits ICD even with LVEF >35% for high-risk calculator scores, while VA 2022 requires meeting the multi-factor threshold. (sources/VA-SCD-ESC-2022, sources/esc-cmp-2023)
• High arrhythmia risk at relatively preserved LVEF: LMNA cardiomyopathy carries a disproportionately high risk of malignant VT compared to non-LMNA DCM with the same LVEF — the standard LVEF ≤35% threshold underestimates risk in this population. Multi-factor ICD thresholds are an attempt to address this, but the optimal combination of risk factors remains unvalidated in prospective studies. (sources/acm-hrs-2019, sources/VA-SCD-ESC-2022)
• LMNA sport restriction evidence gap: The Class III recommendation against competitive sports is based on expert consensus (Level C), not prospective outcome data — in contrast to ARVC, where exercise dose-penetrance data exist. (sources/VA-SCD-ESC-2022)
• Rate control vs. rhythm control in LMNA-AF — guidance exists but prospective data lacking: CJC 2024 characterises rhythm control as "futile" in cardiac laminopathy due to progressive atrial myopathy, and recommends rate control. However, no prospective RCT has evaluated rhythm vs. rate control strategy specifically in LMNA-associated AF. The futility statement is based on clinical observation and small series rather than controlled data. (sources/genetic-af-cjc-2024)
• ESC 2021 vs. ESC 2022 LMNA risk factor list — minor differences: ESC 2021 HF guidelines list 4 risk factors (NSVT, LVEF <45%, male sex, non-missense mutations). ESC VA 2022 uses a similar multi-factor threshold (LVEF <50% + ≥2 of: NSVT, male sex, LGE, inducible SMVT) but with LVEF <50% as a gate. The specific thresholds for LVEF (<45% in ESC 2021 vs. <50% in ESC 2022) are inconsistent. (sources/HF-ESC-2021, sources/VA-SCD-ESC-2022)
• AHA 2022 vs. ESC guidelines on LMNA ICD threshold — converging but not identical: AHA 2022 uses "COR 2a — consideration for ICD even at LVEF >35%," framed as a genetic variant class recommendation. ESC CMP 2023 endorses the LMNA risk-VTA calculator with ≥10% threshold. ESC VA 2022 uses LVEF <50% + ≥2 risk factors. All three agree LVEF ≤35% is an insufficient threshold for LMNA — but specify different frameworks for the expanded threshold. (sources/HF-AHA-2022, sources/VA-SCD-ESC-2022, sources/esc-cmp-2023)

Connections

• Related to sources/conduction-disorders-jaha-2025
• Related to concepts/Conduction-Disorders-in-Young-Adults
• Related to sources/genetic-eoaf-ehj-2024
• Related to sources/genetic-af-cjc-2024
• Related to entities/ALVC
• Related to concepts/Arrhythmogenic-Cardiomyopathy
• Related to concepts/Cascade-Family-Screening
• Related to concepts/Sudden-Cardiac-Death
• Related to concepts/Early-Onset-Atrial-Fibrillation
• Related to entities/NDLVC
• Related to entities/DCM
• Related to concepts/Late-Gadolinium-Enhancement
• Related to concepts/VA-Risk-Stratification-DCM
• Related to sources/HF-ESC-2021
• Related to sources/HF-AHA-2022
• Related to concepts/Genetic-Testing-in-Cardiomyopathy
• Related to sources/genetic-cmp-jcf-2018
• Related to sources/genetic-yield-jama-card-2022

Sources

sources/DCM-Lancet-2023